181,979 IQVIA Holdings Inc. $IQV Shares Acquired by Artemis Investment Management LLP

Key Points

• Artemis Investment Management LLP increased its IQVIA position by 156.9% in the third quarter, acquiring 181,979 additional shares and bringing its holdings to 297,972 shares worth approximately $80.1 million.
• Analysts remain broadly positive, with IQVIA receiving a consensus “Moderate Buy” rating and an average price target of $274.31; several firms recently raised their targets.
• IQVIA exceeded quarterly expectations, reporting $3.15 in adjusted earnings per share and $4.37 billion in revenue, while revenue increased 8.7% year over year. The stock recently traded at $255.37, near its 12-month high of $277.40.

Artemis Investment Management LLP boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 156.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 297,972 shares of the medical research company's stock after acquiring an additional 181,979 shares during the quarter. Artemis Investment Management LLP owned 0.18% of IQVIA worth $80,110,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of IQVIA during the 2nd quarter worth about $2,811,292,000. Boston Partners increased its position in IQVIA by 14.9% during the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company's stock worth $923,276,000 after buying an additional 530,672 shares during the last quarter. JPMorgan Chase & Co. raised its stake in IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company's stock valued at $856,468,000 after buying an additional 528,753 shares during the period. Victory Capital Management Inc. raised its stake in IQVIA by 2,628.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company's stock valued at $377,670,000 after acquiring an additional 1,614,063 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in IQVIA by 9.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company's stock valued at $315,772,000 after purchasing an additional 134,997 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Robert W. Baird raised their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 29th. UBS Group initiated coverage on shares of IQVIA in a report on Wednesday, September 30th. They issued a "buy" rating and a $345.00 price target on the stock. TD Cowen boosted their price objective on IQVIA from $233.00 to $288.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. Stifel Nicolaus upped their target price on IQVIA from $220.00 to $276.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a report on Thursday, July 9th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $274.31.

IQVIA Stock Performance

NYSE IQV traded down $2.74 during trading on Thursday, reaching $255.37. The company's stock had a trading volume of 297,450 shares, compared to its average volume of 1,713,708. The firm has a 50 day moving average price of $256.74 and a 200 day moving average price of $208.40. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $277.40. The firm has a market capitalization of $42.03 billion, a price-to-earnings ratio of 31.71, a price-to-earnings-growth ratio of 2.22 and a beta of 1.17. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm's quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 11.56 EPS for the current fiscal year.

Insider Transactions at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of the firm's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the transaction, the insider owned 10,890 shares in the company, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric Sherbet sold 5,000 shares of the business's stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider directly owned 20,999 shares of the company's stock, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 15,581 shares of company stock worth $3,796,021. Corporate insiders own 1.70% of the company's stock.

About IQVIA

IQVIA Holdings Inc NYSE: IQV is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA's offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.